David R. Spigel

77.8k citations
611 papers · 20.0k indexed · 13 hit papers · h-index 68

Impact in

  • Oncology top 0.05%
    • Lung Cancer Research Studies
    • Cancer Immunotherapy and Biomarkers
    • Colorectal Cancer Treatments and Studies
    • Lung Cancer Treatments and Mutations
    • Lung Cancer Diagnosis and Treatment

Papers in

    • Lung Cancer Research Studies 164
    • Cancer Immunotherapy and Biomarkers 138
    • Colorectal Cancer Treatments and Studies 97
    • Lung Cancer Treatments and Mutations 253
    • Lung Cancer Diagnosis and Treatment 81

David R. Spigel

592 papers receiving 19.6k citations

Hit Papers

Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study 2021 · 251 citations
2512008202620142020200400600

Peers

David R. Spigel
Comparison fields: 5 of 133
  • Oncology 14.4k
  • Pulmonary and Respiratory Medicine 9.9k
  • Cancer Research 2.9k
  • Hepatology 1.0k
  • Pathology and Forensic Medicine 2.3k
Replace Lynette M. Sholl with:
Lynette M. Sholl United States
Antoîne Italiano France
Sylvie Négrier France
Volkan Adsay United States
J. Milburn Jessup United States
Patrick Therasse Belgium
George D. Demetri United States
Jean‐Yves Douillard France
Thierry Le Chevalier France
Keunchil Park South Korea
David R. Spigel relative to Lynette M. Sholl United States Lynette M. Sholl's profile →
Citations per field
00.5×3.0×
Lynette M. Sholl · 1×
Citations per year

Countries citing papers authored by David R. Spigel

Since Specialization
Citations

This map shows the geographic impact of David R. Spigel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David R. Spigel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David R. Spigel more than expected).

Fields of papers citing papers by David R. Spigel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David R. Spigel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David R. Spigel. The network helps show where David R. Spigel may publish in the future.

Co-authorship network

The 25 scholars most cited alongside David R. Spigel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David R. Spigel Line = papers co-authored together David R. Spigel links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20252
2 20241
3 20241
4 20243
5 20241
6 20232
7 202317
8 202321
9 202341
10 20224
11 202156
12
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
Hit paper breakdown →
2019383
13
Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study
Hit paper breakdown →
2018357
14 2017232
15
Results from the phase iii randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage iiib or iv non–small-cell lung cancer: METLung
20171
16
Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer
Hit paper breakdown →
2016397
17 2014120
18 2010135
19
進行性NSCLC患者におけるカルボプラチンとパクリタキセルを併用した,TRAIL-R1アゴニスト単クローン抗体マパツムマブの無作為化第2相試験
20101
20 200978

About David R. Spigel

David R. Spigel is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Pathology and Forensic Medicine and Oral Surgery, having authored 611 papers that have together received 20.0k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (253 papers), Lung Cancer Research Studies (164 papers), Cancer Immunotherapy and Biomarkers (138 papers), Cancer Genomics and Diagnostics (97 papers), Colorectal Cancer Treatments and Studies (97 papers), Lung Cancer Diagnosis and Treatment (81 papers), Cancer therapeutics and mechanisms (56 papers) and Neuroendocrine Tumor Research Advances (55 papers). The work is most often cited by research in Oncology (14.4k citations), Pulmonary and Respiratory Medicine (9.9k citations), Cancer Research (2.9k citations), Hepatology (1.0k citations) and Pathology and Forensic Medicine (2.3k citations). David R. Spigel has collaborated with scholars based in United States, United Kingdom and Spain. Frequent co-authors include John D. Hainsworth, F. Anthony Greco, Howard A. Burris, Scott Antonia, David Waterhouse, Scott Gettinger, Julie R. Brahmer, Lecia V. Sequist, Mark A. Socinski and Tony Mok. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal of Thoracic Oncology, Cancer Research and Clinical Lung Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026